Role of Anomalous Water Constraints in the Efficacy of Pharmaceuticals Probed by 1H Solid‐State NMR by Damron, Joshua T. et al.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
Supporting Information
 Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2017
Role of Anomalous Water Constraints in the Efficacy of
Pharmaceuticals Probed by 1H Solid-State NMR
Joshua T. Damron+, Kortney M. Kersten+, Manoj Kumar Pandey, Yusuke Nishiyama,
Adam Matzger,* and Ayyalusamy Ramamoorthy*
	 S1	
 
Table of Contents 
SI 1. Experimental 
SI 2. Pharmaceutical hydrate statistics 
SI 3. Supporting NMR Data 
SI 4. Infrared Spectroscopy 
SI 5. Theoretical calculation data for mercaptopurine hydrate forms 
SI 7. References 
 
SI 1. Experimental Procedures 
Experimental Section 
Materials 
Mercaptopurine monohydrate, deuterated methanol (MeOD), and D2O were obtained from Acros. 
Methanol was obtained from Fisher Scientific. All reagents were used without further purification. 
The purity of the material, from which the hydrates were made, as received from the distributor is 
99.5%.   
Crystallization 
Crystallization of the hydrates were produced in the manner reported by Kersten et. al.[1] Crystals 
of the monohydrate form were grown from methanol solutions (4 mg/mL) heated to 80 °C to 
dissolve all solids. Solutions were passed through a syringe filter (9 mL) into a 20 mL vial 
containing 5 mL H2O. Vials were sealed and yellow block-shaped crystals grew after two days at 
room temperature. Crystals of the hemihydrate form were grown from methanol solutions (4 
mg/mL) heated to 80 °C to dissolve all solids. Solutions were passed through a syringe filter (4.5 
mL) into a 20 mL vial containing 0.5 mL H2O. Vials were sealed and yellow needle crystals grew 
after two days at room temperature.   
Samples of both the monohydrate and hemihydrate forms were also created using MeOD and 
D2O to crystallize samples with deuterated nitrogens and water molecules (See Section S4, 
Figure S8) 
Infrared Spectroscopy  
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Fourier transform infrared spectroscopy analyses were performed on the hemihydrate and 
monohydrate forms of mercaptopurine using an attenuated total reflectance accessory (ATR; 
ThermoNicolet Avatar model 360-FTIR). The scan range was 680 to 4000 cm-1, employing 512 
scans with a resolution of 4 cm-1. Samples were analyzed on the ATR stage and the empty stage 
was used as the blank.  
NMR Spectroscopy 
All mercaptopurine CSA/CS data were acquired on a JEOL ECZ600R at 600 MHz 1H Larmor 
frequency using a JEOL RESONANCE Inc. 0.75 mm double-resonance MAS probe under 90 kHz 
+/- 20 Hz MAS at room temperature (25 °C).  Six scans were used with a recycle delay of 120 s 
and 32 t1 points in all experiments. The decoupled spectra were obtained with 14N-1H decoupling 
(99W/~117 kHz) using an on-resonance 14N irradiation during the 1H CSA recoupling t1 period to 
avoid the reintroduction of 14N-1H dipolar interactions.  
 
2D CS/CSA pulse sequence 
  
Figure S1. Schematic of the radio-frequency pulse sequence used for all CS/CSA correlations experiments. 
The solid black rectangles in the 1H RF channel are 90° and 180° pulses.  
 
The pulse sequence[2,3] used for CSA/CS correlation depicted in Figure S1 is a gamma-encoded 
symmetry based pulse sequence for selective recoupling of the 1H CSA anisotropy. The notation 
R1887(270°90°) comes from the symmetry principles for pulse sequence design introduced by  
Levitt and co-workers.[4,5] The general notation RNnν refers to N, the number of phase-alternated 
composite pulses, n the number of rotor periods, and ν determines the phase of the pulses by 𝜋𝑣/𝑁. In this case, (270°90°) is a composite 180° pulses whose phase alternates between (70°, 
250°) and (-70°, -250°). The proper choice of N, n and ν determine which interactions are retained 
according to the symmetry of the first-order Hamiltonian. In this case, the symmetry renders the 
CSA and heteronuclear dipolar couplings. To limit the evolution in t1 strictly to CSA, heteronuclear 
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decoupling is applied on the 14N channel. This is necessary for abundant hetero-nuclei, such as 
14N. Given the low natural-abundance of 13C and 15N, it is not necessary to apply decoupling on 
these RF channels, as only very small fractions of 1H spins are affected. The proton magnetization 
is then refocused by a spin-echo to suppress background signals and then detected in the t2 
period where the isotropic chemical shift is encoded in the magnetization. The experimentally 
measured spectrum gives a bimodal line-shape in the t1 dimension whose splitting is roughly 
proportional to the magnitude of the CSA, while the shape of the line is related to the asymmetry 
parameter, or shape of the CSA tensor. The experimentally measured line-shapes are numerically 
simulated using SIMPSON software to extract the CSA and asymmetry parameters. The reported 
SS NMR parameters are the CSA, defined as z = dzz- diso, and the asymmetry parameter 
h = (dxx-dyy)/z, where diso is the trace of the CSA tensor (or the isotropic chemical shift), and dii are 
its principal components ordered as |dzz - diso| ³ |dxx - diso| ³ |dyy - diso|. 
 
Charge Density Map Calculations 
Computation of the charge density maps of the two tautomeric forms of mercaptopurine were 
performed in Spartan ‘14 V 1.1.2. The energy of the initial structure was minimized using 
molecular mechanics (MMFF). The equilibrium geometry was calculated using density functional 
theory B3LYP with the basis set 6-31G* in the gas phase. The electrostatic potential map surface 
was calculated and then displayed.  
        Geometry optimization was first performed on all structures where all atoms except hydrogen 
were held at a constant position. The unit cell parameters were also held constant, and the 
calculations were performed using an ultra-fine quality with the COMPASS II force field assigned, 
which is parameterized for the functional groups present. This initial optimization gave the total 
energy for the initial crystal structures containing the water molecules. For both the hemi and 
monohydrate systems, the water molecules were deleted and energy calculations were performed 
again using the COMPASS II force field assigned to give a total energy for the system after 
theoretical water loss. Density functional theory calculations were also performed before and after 
deletion of the water molecules for each structure using two different modules. Preoptimization of 
the structures was performed using the only H free molecular mechanics method above. For the 
CASTEP module, ultrafine energy calculations were then performed using the GGA-PW91 theory. 
This gave the energy for the system containing water molecules. The water molecules were then 
deleted and energy calculations were performed again using the GGA-PW91 theory to give the 
energy for the system after theoretical water loss. For the Dmol3 module, fine geometry 
optimization calculations with the GGA-PW91 theory were performed on the preoptimized 
structures using the only H free molecular mechanics method above. The water molecules were 
then deleted and fine energy calculations were performed again using the GGA-PW91 theory to 
determine the energy for the system after theoretical water loss. Figure S9 and Tables S4 and S5 
show the above-mentioned free energy values and the method and results for the calculation of 
theoretical desolvation energies for each form. 
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Calculated IR Spectroscopy Stretches 
The theoretical IR stretches for both the monohydrate and hemihydrate forms of mercaptopurine 
were calculated using DFT calculations in Materials Studio 7.0. The same geometry optimizations 
were performed following the desolvation energy calculations above; first by using Molecular 
Mechanics (Forcite with COMPASS II) and then DFT (Dmol3) to get an optimized structure of 
each form. The frequency values of each form were then calculated using DFT methods by way 
of medium frequency analysis as a property in the Dmol3 calculation using the GGA-PW91 theory. 
Vibrational analysis was performed, the modes were calculated, and the frequencies were 
animated to determine the appearance of OH stretches of each hydrate form.     
 
SI 2. Pharmaceutical Hydrate Statistics 
Table S1.  Database of pharmaceutical compounds created from listings of the top selling pharmaceuticals 
by prescriptions from 2005-2015.[6–11]  
 Pharmaceutical (Brand Name) Solid form 
1 Abilify Anhydrate 
2 Aciphex Salt 
3 Actonel Salt 
4 Actos Salt 
5 Adderall XR Salt 
6 Advair  Salt and Anhydrate 
7 Afinitor Anhydrate 
8 Allegra Salt 
9 Allegra-D Salts 
10 Altace Anhydrate 
11 Amaryl Anhydrate 
12 Ambien Salt 
13 Anoro Ellipta Salts 
14 Aricept Salt 
15 Armour Thyroid Anhydrates 
16 Atripla Salt and Anhydrates 
17 Avalide Anhydrates 
18 Avandia Salt 
19 Avapro Anhydrate 
20 Avelox Salt 
21 Aviane/ Seasonique Anhydrates 
22 Belviq Salt Hydrate (Hemi) 
23 Benicar Anhydrate 
24 Benicar HCT Anhydrates 
25 Boniva Salt Hydrate (Mono) 
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26 Breo Ellipta Salt and Anhydrate 
27 Brisdelle Salt 
28 Budeprion SR/ Wellbutrin XL Salt 
29 Bystolic Salt 
30 Caduet Salt and Salt Hydrate (Tri) 
31 Celebrex  Anhydrate 
32 Chantix Salt 
33 Cialis Anhydrate 
34 Clarinex Anhydrate 
35 Combivent Salt and Salt Hydrate (Mono) 
36 Complera Anhydrate and Salts 
37 Concerta/ Quillivant XR Salt 
38 Coreg Anhydrate 
39 Coumadin  Salt 
40 Cozaar Salt 
41 Crestor Salt 
42 Cymbalta Salt 
43 Depakote ER Salt 
44 Detrol LA Salt 
45 Dexilant Anhydrate 
46 Digitek/ Lanoxin  Anhydrate 
47 Diovan  Anhydrate 
48 Diovan HCT Anhydrates 
49 Duavee Salt and Anhydrate 
50 Dulera Anhydrate and Salt Hydrate (Di) 
51 Effexor XR Salt 
52 Eliquis Anhydrate 
53 Endocet Salt and Anhydrate 
54 Evista Salt 
55 Farxiga 
Hydrate (Mono) Solvate 
(1,2Propanediol) 
56 Flomax Salt 
57 Flovent/ Flonase Anhydrate 
58 Focalin  Salt 
59 Fosamax Salt Hydrate (Tri) 
60 Geodon Oral Salt Hydrate (Mono) 
61 Gilenya Salt 
62 Gleevec Salt 
63 Glipizide XL Anhydrate 
64 Hyzaar Salt and Anhydrate 
65 Imitrex Salt 
66 Intuniv Salt 
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67 Invega Sustenna Anhydrate 
68 Invokana Hydrate (Hemi) 
69 Isentress Salt 
70 Janumet Salt and Salt Hydrate (Mono) 
71 Januvia Salt Hydrate (Mono) 
72 Kariva Anhydrates 
73 Klor-Con Salt 
74 Lamictal Anhydrate 
75 Latuda Salt 
76 Levaquin Hydrate (Hemi) 
77 Levitra Salt Hydrate (Tri) 
78 Lexapro Salt 
79 Lipitor Salt Hydrate (Tri) 
80 Livalo Salt 
81 Loestrin 24 Fe Anhydrate and Salt 
82 Lotrel  Salts 
83 Lunesta Anhydrate 
84 Lyrica Anhydrate 
85 Micardis Anhydrate 
86 Mirapex Salt Hydrate (Mono) 
87 Mobic Anhydrate 
88 Monodox Hydrate (Mono) 
89 Myrbetriq Anhydrate 
90 Namenda Salt 
91 Nasacort AQ Anhydrate 
92 Nasonex Hydrate (Mono) 
93 Nexium Salt Hydrate (Tri) 
94 Niaspan  Anhydrate 
95 Norvasc Salt 
96 Omnaris Anhydrate 
97 Omnicef Anhydrate 
98 Onglyza Salt Hydrate (Mono) 
99 Ortho Evra/Trinessa/Tri-Sprintec/Yasmin 28 Anhydrates 
100 Osphena Anhydrate 
101 Oxycontin Salt 
102 Paxil CR Salt Hydrate (Hemi) 
103 Plavix Salt  
104 Pradaxa Salt 
105 Pravachol Salt 
106 Premarin Anhydrate 
107 Prempro Anhydrates 
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108 Prevacid Anhydrate 
109 Prezista Solvate (Ethanol) 
110 Prilosec Anhydrate 
111 Pristiq Salt Hydrate (Mono) 
112 Proair/ Proventil/ Ventolin HFA Salt 
113 Protonix Salt Hydrate (Sesqui) 
114 Provigil  Anhydrate 
115 Relpax Salt 
116 Requip Salt 
117 Reyataz Salt 
118 Rhinocort Aqua Anhydrate 
119 Risperdal  Anhydrate 
120 Sensipar Salt 
121 Seroquel Salt 
122 Singulair Salt 
123 Skelaxin Anhydrate 
124 Solodyn Salt 
125 Sovaldi Anhydrate 
126 Spiriva Salt Hydrate (Mono)  
127 Strattera Salt 
128 Stribild Anhydrates and Salt 
129 Suboxone Salt and Salt Hydrate (Di) 
130 Symbicort Salt Hydrate (Di) and Anhydrate 
131 Synthroid/ Levoxyl/ Levothyroid Salt Hydrate (Channel) 
132 Tamiflu Salt 
133 Tecfidera Anhydrate 
134 Topamax Anhydrate 
135 Toprol XL Salt 
136 Toviaz Salt 
137 Tricor Anhydrate 
138 Trilipix Salt 
139 Truvada Salt and Anhydrate 
140 Tussionex  Salts  
141 Uloric Anhydrate 
142 Valtrex Salt 
143 Vesicare Salt 
144 Viagra Salt 
145 Vicodin Anhydrate and Salt Hydrate (2.5) 
146 Vimovo Anhydrate and Salt Hydrate (Tri) 
147 Vytorin Anhydrates 
148 Vyvanse Salt 
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149 Xarelto Anhydrate 
150 Xeljanz Salt 
151 Xeloda Anhydrate 
152 Xopenex Salt 
153 Yaz-28 Anhydrates 
154 Zetia Anhydrate 
155 Zithromax Hydrate (Di) 
156 Zocor Anhydrate 
157 Zoloft Salt 
158 Zyprexa Anhydrate 
159 Zyrtec Salt 
160 Zyrtec-D Salts 
161 Zytiga Anhydrate 
 
Table S2.  Statistical data for each solid form type from the database in table S1.  
 Hydrates 
Salt 
Hydrates Salts  Anhydrates Total 
Total 6 23 75 56 160 
Percent 3.75 14.38 46.88 35.00 100.01 
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SI 3. Supporting NMR Data 
Additional NMR experiments were performed for resonance assignment. First, the hydrates were 
prepared using MeOD and D2O, which replace the water molecules as well as exchange the NH 
protons revealing only the aromatic resonances in the 1H spectrum. Figure S7 (c and d) shows 
the deuterated samples, confirming the aromatic position at slightly above 8 ppm for both hydrate 
forms. For comparison, the fully protonated 1D spectra are shown in the top part of Figure S7 (a 
and b).  
In addition, the CSA measurements were run without 14N decoupling, allowing the through space 
14N-1H heteronuclear dipolar interaction to also contribute the line-shape as well as the CSA. As 
such, a comparison of the two allows for easy identification of the NH resonances. Figure S8 
shows this comparison where the most downfield resonances in both cases are severely 
broadened by the lack of decoupling, confirming the NH resonance assignments. The CSA 
numbers including with and without decoupling are summarized in Table S3. The NH resonances 
are so distorted their lines could not be fit. 
 
 
 
 
Figure S2. 1H spin-echo of mercaptopurine: (a) monohydrate with H2O, (b) hemihydrate with H2O, 
(c) monohydrate with MeOD/D2O and (d) hemihydrate with MeOD/D2O. The H/D exchange was 
used for confirmation of exchangeable peaks. By this method, all NH and OH hydrogens are 
replaced with deuterium.  
a)	
d)	c)	
b)	
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Figure S3.1H CS/CSA correlation recorded with (bottom) and without (top) 14N decoupling. The 
downfield resonances are clearly most influenced by the presence of 14N heteronuclear dipolar 
interaction identifying those as directly bonded.  
Table S3. Comparison of 1H CSA values with and without 14N decoupling. 
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SI 4. Infrared Spectroscopy 
 
 
Figure S4. Experimental IR spectrum of the monohydrate form of mercaptopurine with labels 
based on computational predictions. [Note: imd=imidazole ring, pyr=pyrimidine ring] 
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Figure S5. Structural depiction of the calculated stretching for the OH hydrogen bound to sulfur 
(left, 3428.9 cm-1 experimentally) and the OH hydrogen bound to nitrogen (right, ~3160 cm-1 
experimentally) for the monohydrate form of mercaptopurine.  
 
 
 
 
 
Figure S6. Structural depiction of the experimental unit cell of the monohydrate form of 
mercaptopurine with the OH hydrogen bonds highlighted (OH…S is 2.40 Å, OH…N is 1.82 Å).  
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Figure S7. Experimental IR spectrum of the hemihydrate form of mercaptopurine with labels 
based on computational predictions. [Note: imd=imidazole ring, pyr=pyrimidine ring] 
             
Figure S8. Structural depiction of the symmetric OH stretching (left, 3444.4 cm-1 experimentally) 
and asymmetric OH stretching (right, 3500.3 cm-1 experimentally) calculated for the hemihydrate 
form of mercaptopurine. 
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SI 5. Theoretical calculation data for mercaptopurine hydrate forms  
Theoretical Desolvation Energy Calculations 
The crystal structure for the monohydrate form was taken from the Cambridge Structural 
Database (RefCode: MERPUM)[12]. The crystal structure for the hemihydrate form was solved in 
house. All modules used were part of the Materials Studio 7.0 suite. Bonds were calculated if 
necessary and correct bond orders were assigned based on the crystal structures. The following 
procedures were optimized based on previous literature.[13]  
Figure S9. Depiction of how the theoretical desolvation energy calculations were derived.  
 
 
 
 
Using the concept that the energy of the desolvation process is products – reactants, this gives 
the following two equations: 4	𝐻(𝑂 + 𝐸2 − 𝐸1 = 	𝐸0123	415678      (1)    8	𝐻(𝑂 + 𝐸4 − 𝐸3 = 	𝐸26;6	415678      (2)  
Rearranging equation 1 for the water gives: 4	𝐻(𝑂 = 	𝐸0123	415678 − 𝐸2 + 𝐸1         (3) 
Multiplying equation 3 by 2 and substituting in for 4H2O in equation 1 gives:  𝐸4 + {2 𝐸0123	415678 − 𝐸2 + 𝐸1 } − 𝐸3 = 𝐸26;6	415678        (4) 
Rearranging equation 4 gives equation 5, in which we can calculate the difference in desolvation 
energies between the two forms (in terms of the number of water molecules per structure) based 
on the 4 energies which were calculated using the above computational methods: 
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𝐸4 − 𝐸3 − 2𝐸2 + 2𝐸1 = 	𝐸26;6	415678	 − 2𝐸0123	415678      (5) 
Table S4 shows the energies for each structure (E1-E4) calculated by each of the three 
computational methods. The results of equation 5 for each method are shown in Table S5. The 
magnitude of each calculation is different, which shows that each computational method takes 
different interactions into account. However, each method shows that the monohydrate has a 
higher theoretical desolvation energy, indicating that the water molecules are held in more tightly 
from an energetic standpoint (i.e. more strongly hydrogen bound) than the water molecules in the 
hemihydrate.  
 
 
Table S4. Geometry optimization and energy calculations for the two hydrate forms of 
mercaptopurine using three different computational methods.   
Method Forcite (E1) Forcite (E2) CASTEP (E1) CASTEP (E2) Dmol3 (E1) Dmol3 (E2) 
Energy 402.47 164.54 -449,930.31 -406,551.36 -4,259,328.10 -4,067,404.30 
       
 Forcite (E3) Forcite (E4) CASTEP (E3) CASTEP (E4) Dmol3 (E3) Dmol3 (E4) 
Energy 637.31 272.42 -493,311.58 -406,483.05 -4,451,283.30 -4,067,335.30 
 
Table S5. Difference in theoretical desolvation energies calculated from the values in table S4 
using equation 5 above. These values represent  𝐸26;6	415678	 − 2𝐸0123	415678.       
Computational 
method Forcite CASTEP Dmol3 
Energy per unit cell 
(kcal/mol) 
110.97 70.63 100.40 
Energy per water 
molecule (kcal/mol) 
13.87 8.83 12.55 
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